Proactive Investors - Run By Investors For Investors

Alliance Pharma on target to meet market expectations after a solid first-half

Revenues were up 10% in the first six months of the year as the company's star brands performed strongly
Vanousse advert
Vamousse, a head lice treatment, is one of the company's international star brands

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical group, said it is trading in line with expectations.

In an update, it said revenues for the six months ended June 30 rose 10% to £54.4mln, though trading profit tracked at a slightly slower pace due largely to the phasing of marketing spend.

The company’s star international brands MacuShield, Vamousse and Kelo-Cote delivered “strong performances”, investors were told. The latter, a treatment for scarring, saw its sales increase 77% to almost £11mln.

Revenues from what Alliance calls local hero brands were in line with forecasts.

Cash flow remained strong

The company said its top line was negatively affected by currency fluctuations to the tune of £900,000.

Underlying free cash flow was £10.1mln, while net debt increased by £14mln to £86.3mln as it funded acquisitions such as the purchase of medicated anti-dandruff shampoo, Nizoral.

The company said it expects to launch anti-nausea treatment Xonvea in the UK in the autumn.

“On the basis of trading in the year to date, the board expects revenue and underlying profit before tax for the current financial year to be in line with expectations,” the market was told.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use